Elutia Inc. (ELUT) stock
ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/309% below fair value
$0.83−0.02 (-2.80%)
Close on Nov 18, 2026Market cap $36.76MP/E –Yield –
Elutia net income
Net income is the profit left for shareholders after every expense, interest and tax.
Elutia's net income for the twelve months ending Jun 30, 2026 was $51.81M. For fiscal 2025 it was $53.38M. The highest annual figure on record is $53.38M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.38M | – |
| FY2024 | Dec 31, 2024 | -$53.95M | – |
| FY2023 | Dec 31, 2023 | -$37.66M | – |
| FY2022 | Dec 31, 2022 | -$32.90M | – |
| FY2021 | Dec 31, 2021 | -$24.83M | – |
| FY2020 | Dec 31, 2020 | -$21.83M | – |
| FY2019 | Dec 31, 2019 | -$11.94M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.65M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.47M | – |
| Q4 FY2025 | Dec 31, 2025 | $70.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.87M | -400.8% |
| Q2 FY2025 | Jun 30, 2025 | -$9.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.06M | – |
| Q3 FY2024 | Sep 30, 2024 | $1.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$28.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.75M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.97M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.15M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.06M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.32M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.07M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.36M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.73M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.18M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.56M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.78M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.10M | – |
See a number that looks wrong?